Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~Patients must meet all of the following inclusion criteria to be eligible for participation in this study:~* Patients or their legal representative(s) must provide written informed consent prior to undergoing any study-related procedures~* Patients must be ≥ 13 and ≤ 65 years of age at the time of study enrollment~* Female patients of childbearing potential and sexually mature males must agree to use a medically acceptable form of birth control; for the purposes of this study, females are considered of non-childbearing potential if they are surgically sterile (i.e., have undergone a total hysterectomy, bilateral salpingo-oophorectomy or tubal ligation) or are post-menopausal, defined as having complete cessation of menstruation for at least 1 year after 45 years of age~* Patients must have a pre-established clinical diagnosis of HPP as indicated by:~  * Serum alkaline phosphatase (ALP) below the age-adjusted normal range~ * Plasma PLP at least twice the upper limit of normal (no vitamin B6 administered for at least 1 week prior to determination)~ * Evidence of osteopenia or osteomalacia on skeletal radiographs~* Patients must have osteomalacia on bone biopsy, characterized by an MLT z-score of +2 or more (results from ENB-001-08 may be used)~* Patients must be willing to comply with study procedures and the visit schedule~Exclusion criteria:~Patients will be excluded from participation in this study if they meet any of the following exclusion criteria:~* Women who are pregnant or lactating~* History of sensitivity to tetracycline~* Serum calcium or phosphate levels below the normal range~* Serum 25(OH) vitamin D below 20 ng/mL~* Serum creatinine or parathyroid hormone (PTH) levels above the upper limit of normal~* Medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities~* Orthopedic surgery within 12 months prior to study entry that may interfere with the ability to perform functional assessments for the study~* Prior treatment with bisphosphonates within 2 years of study entry for any length of time or for more than 2 years at any time point; for patients with prior bisphosphonate use that is allowed, the bone resorption markers serum C-telopeptide and urine N-telopeptide or urine deoxypyridinoline must also be within the normal range or elevated to be eligible for study participation~* Treatment with PTH within 6 months prior to the start of asfotase alfa administration~* Participation in an interventional or investigational drug study within 30 days prior to study participation

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (2.1 mg/kg/week total)
- Cohort 2 (Type: EXPERIMENTAL): Cohort 2: Daily SC injections of 0.5 mg/kg asfotase alfa (3.5 mg/kg/week total)
- Concurrent Control (Type: NO_INTERVENTION): Following completion of the Week 24 visit, all patients (including those randomized to the concurrent control cohort) may be eligible to participate in an open-label extension treatment period. In this extension period, all patients will be treated with daily SC injections of 0.5 mg/kg/day asfotase alfa (a total of 3.5 mg/kg/week) for approximately 24 weeks, then subjects will receive 1 mg/kg/day 6 days/week for an additional 48 weeks or until regulatory approval of the drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).